WALTHAM, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced that Remy Luthringer, PhD, president and chief scientific officer at Minerva, will present a review of company pipeline research in a panel discussion at the CNS Summit meeting being held at the Boca Raton Resort and Club in Boca Raton, Florida, November 13-16, 2014.
Dr. Luthringer's presentation will take place during the CNS Summit Scientific Session being held from 9 AM to noon ET on Sunday, November 16, 2014.
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat neuropsychiatric diseases. Minerva is developing a portfolio of first-in-class proprietary compounds, including lead compound MIN-101, which is in Phase 2 trials for schizophrenia, and additional candidates targeting major depressive disorder (MDD), insomnia and other CNS disorders. Minerva's common stock is listed on the NASDAQ Global Market where it trades under the symbol "NERV." For more information, please visit www.minervaneurosciences.com/.
CONTACT: Media Contact: David Salisbury Berry & Company Public Relations Tel: 212-253-8881 firstname.lastname@example.org Investor Contact: Renee Leck Stern Investor Relations Tel: 212-362-1200 email@example.comSource:Minerva Neurosciences, Inc